SCHEMBL700760

SCHEMBL700760

Fc1ccc(/C=C/c2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 11/20 1.00
MAOB P27338 2/20 0.56
CYP19A1 P11511 1/20 0.56
MAOA P21397 1/20 0.56
APP P05067 1/20 0.54
PTGS1 P23219 1/20 0.54
RELA Q04206 1/20 0.50
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL700761 1.00 NFE2L2 (1.00) NFE2L2MAOBCYP19A1MAOAAPP
SCHEMBL4946969 1.00 NFE2L2 (1.00) NFE2L2MAOBCYP19A1MAOAAPP
SCHEMBL18867936 1.00 NFE2L2 (1.00) NFE2L2MAOBCYP19A1MAOAAPP
SCHEMBL13766558 0.88 NFE2L2 (0.78) NFE2L2APPPTGS1
SCHEMBL13766470 0.88 NFE2L2 (0.78) NFE2L2APPPTGS1
SCHEMBL700052 0.88 NFE2L2 (0.78) NFE2L2APPPTGS1
SCHEMBL700051 0.88 NFE2L2 (0.78) NFE2L2APPPTGS1
SCHEMBL22468800 0.88 NFE2L2 (0.78) NFE2L2APPPTGS1
SCHEMBL11547655 0.85 NFE2L2 (0.72) NFE2L2MAOBCYP19A1MAOARELA
SCHEMBL44504 0.85 NFE2L2 (0.72) NFE2L2MAOBCYP19A1MAOARELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404221-B2 Methods of arene alkenylation UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2025-09-02 US disclosed
US-11858889-B2 Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease THE TRUSTEES OF INDIANA UNIVERSITY (US) 2024-01-02 US disclosed
US-20230234900-A1 METHODS OF ARENE ALKENYLATION UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2023-07-27 US disclosed
US-20230234900-A1 METHODS OF ARENE ALKENYLATION UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2023-07-27 US disclosed
US-20230234900-A1 METHODS OF ARENE ALKENYLATION UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2023-07-27 US disclosed
US-20220023172-A1 COSMETIC COMPOSITIONS AND METHODS OF USE TRUJILLO KRISTINA (US) 2022-01-27 US disclosed
CN-113788733-A Deuterated method of trans-olefin 五邑大学 2021-12-14 CN disclosed
US-20210205800-A1 YLIDE-FUNCTIONALISED PHOSPHANES FOR USE IN METAL COMPLEXES AND HOMOGENEOUS CATALYSIS UMICORE AG & CO. KG (DE) 2021-07-08 US disclosed
WO-2021074275-A1 EFFECTIVE PHOTOMODULATION OF LANTHANIDE (III) ION LUMINESCENCE IN THE VISIBLE OR NEAR-INFRARED RANGE UNIVERSITE DE RENNES 1 (FR) 2021-04-22 WO disclosed
US-10940470-B2 Ylide-functionalised phosphanes for use in metal complexes and homogeneous catalysis UMICORE AG & CO. KG (DE) 2021-03-09 US disclosed
US-20050244742-A1 Reimageable medium with light absorbing material XEROX CORPORATION 2005-11-03 US disclosed
US-20050244743-A1 Reimageable medium XEROX CORPORATION. 2005-11-03 US disclosed
EP-1591830-A2 Reimageable medium Xerox Corporation (US) 2005-11-02 EP disclosed
EP-1591831-A2 Reimageable medium with light absorbing material Xerox Corporation (US) 2005-11-02 EP disclosed
EP-1591829-A1 Method for forming temporary image Xerox Corporation (US) 2005-11-02 EP disclosed
US-5759729-A A DRY TONER COMPRISING A RESIN, PHOTOCHROMATIC SPIROPYRAN, -OXAZINE OR -THIOPYRAN DYE AND A CHARGE CONTROL AGENT;ELECTROGRAPHY; XEROGRAPHY XEROX CORPORATION (US) 1998-06-02 US disclosed
US-5710420-A Method for embedding and recovering machine-readable information XEROX CORPORATION (US) 1998-01-20 US disclosed
US-5633109-A Ink compositions with liposomes containing photochromic compounds XEROX CORPORATION (US) 1997-05-27 US disclosed
US-5593486-A Photochromic hot melt ink compositions XEROX CORPORATION (US) 1997-01-14 US disclosed
US-5551973-A LIQUID CRYSTAL GEL PHASE, MICROEMULSION PHASE XEROX CORPORATION (US) 1996-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234900-A1 METHODS OF ARENE ALKENYLATION CYBB, CBR3, AHR NFE2L2 102/4885MAOB 157/4885CYP19A1 504/4885
US-20220023172-A1 COSMETIC COMPOSITIONS AND METHODS OF USE NFKBIA, IKBKB, NFKB2 NFE2L2 9/4885MAOB 215/4885CYP19A1 249/4885
US-12404221-B2 Methods of arene alkenylation CYBB, CBR3, AHR NFE2L2 102/4885MAOB 157/4885CYP19A1 504/4885
US-11858889-B2 Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease ADM2, DDAH1, BHMT NFE2L2 713/4885MAOB 544/4885CYP19A1 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.